Breaking News Headlines Today

News from Eyewire+

Stay current with all the latest and breaking news from Eyewire+. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 114 have been published by Eyewire+ which Ground News has aggregated in the past 3 months.

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

Why Is STAAR Surgical Stock Skyrocketing Tuesday? - Staar Surgical (NASDAQ:STAA), Alcon (NYSE:ALC)

86% Center coverage: 7 sources

Alcon will acquire STAAR Surgical for $1.5 billion to expand surgical vision correction options for high myopia, including EVO ICL lenses.See the Story

United States · United States

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

60% Left coverage: 5 sources

MILAN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AAVB-039, the company's gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug (IND) application for …See the Story

United States · United States

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for Registrational Trial of AXPAXLI

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).See the Story

Genentech reports five-year data from trial of Susvimo for wet AMD

Roche’s Genentech has reported new five-year data from the Phase III Portal trial of Susvimo for treating wet AMD.The post Genentech reports five-year data from trial of Susvimo for wet AMD appeared first on Clinical Trials Arena.AMD See the Story

First FDA-Approved Treatment for MacTel Performed

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.See the Story

Avista Therapeutics and Forge Biologics Partner to Advance Gene Therapy for X-Linked Retinoschisis

Avista Therapeutics and Forge Biologics have announced a strategic partnership to accelerate the development and manufacturing of AVST-101, Avista’s lead gene therapy candidate for X-linked retinoschisis (XLRS). AVST-101 is a next-generation gene therapy engineered for efficient intravitreal delivery, low-dose efficacy, and broad retinal coverage, aiming to provide a safer and more accessible treatment option for patients. “Partnering with Avist…Columbus, Ohio · Columbus Read Article

Myra Vision Receives FDA Approval For Glaucoma Study

The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical SystemBoston, Massachusetts · Boston See the Story

Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report

Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS). The TFOS DEWS III report, published in the June 2025 issue of the American Journal of Ophthalmology, cites two clinical studies evaluating Nordic Pharma’s crosslinked hyaluron…Maryland · Maryland Read Article

PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHT

PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). PA5108 is a new chemical entity (NCE) and prodrug of latanoprost acid engineered to deliver consistent IOP-lowering therapy over a 6-month period following a sing…United States · United States Read Article

LKC Technologies: RETeval DR Score Superior in Predicting Diabetic Retinopathy Outcomes

LKC Technologies, a provider of electroretinography (ERG)-based functional diagnostics, announced the publication of a study that found that ERG/pupillometry outperforms structural imaging in identifying patients at highest risk of progressing to vision-threatening complications over 1 year. The post-hoc analysis, which evaluated 56 parameters across four modalities: ERG/pupillometry, UWF-FA, OCTA, and fundus photography, was published in Ophtha…Read Article

4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME

4D Molecular Therapeutics (4DMT) announced interim results from its SPECTRA phase 2a clinical trial evaluating 4D-150 for diabetic macular edema (DME). The data were presented at the 43rd Annual American Society of Retina Specialists (ASRS) scientific meeting by David Almeida, MD, PhD.[1] Key Takeaways 1. Durable Visual and Anatomic Response at Phase 3 Dose Patients receiving the Phase 3 dose (3E10 vg/eye) of 4D-150 demonstrated: +9.7 letter…FDA · Maryland Read Article

News from Eyewire+

News from Eyewire+

Information about Eyewire+

Media Bias Ratings

Factuality

Ownership

Top Eyewire+ News

Why Is STAAR Surgical Stock Skyrocketing Tuesday? - Staar Surgical (NASDAQ:STAA), Alcon (NYSE:ALC)

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for Registrational Trial of AXPAXLI

Genentech reports five-year data from trial of Susvimo for wet AMD

First FDA-Approved Treatment for MacTel Performed

Avista Therapeutics and Forge Biologics Partner to Advance Gene Therapy for X-Linked Retinoschisis

Myra Vision Receives FDA Approval For Glaucoma Study

Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report

PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHT

LKC Technologies: RETeval DR Score Superior in Predicting Diabetic Retinopathy Outcomes

4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME

Similar News Topics

Topics Most Covered by Eyewire+

Sources Covering Similar Topics

Breaking News Topics Related to Eyewire+

Information about Eyewire+

Media Bias Ratings

Factuality

Ownership

Genentech reports five-year data from trial of Susvimo for wet AMD

First FDA-Approved Treatment for MacTel Performed

Avista Therapeutics and Forge Biologics Partner to Advance Gene Therapy for X-Linked Retinoschisis

Myra Vision Receives FDA Approval For Glaucoma Study

Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report

PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHT

LKC Technologies: RETeval DR Score Superior in Predicting Diabetic Retinopathy Outcomes

4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME